Announced Tue, 7 Jul · 10:12 IST
Routine compliance certificate filing for quarter ended June 2026
Compliance View source PDF
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-2.7%1-day move
₹3375.00
prior close
₹3326.00
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.4-0.6-0.6-0.7-2.7-2.1-0.3+1.5+1.2+2.3————
Up moveDown movePending
AI summary
Ajanta Pharma submitted a routine certificate under SEBI Regulation 74(5) for the quarter ended 30 June 2026. The certificate from their Registrar and Share Transfer Agent, MUFG Intime India, confirms that securities received for dematerialisation during the quarter were duly processed, confirmed to depositories, and the company name was substituted in the register of members within the prescribed timelines. This is a standard procedural compliance filing with no business or financial disclosure.
Likely market impact
Routine regulatory compliance filing. No material impact on shareholders, operations, or stock price.